Victoria Sung testified about speaking to Theranos in 2009 about helping the biopharmaceutical company in a drug trial for a medication in development to treat anemia. She said that the small, compact size of the Theranos devices appealed to her, the Wall Street Journal reports.
Sung alleged that Celgene vetted the Theranos technology against “gold-standard” blood testing partners and did not have confidence in the results. She testified that the results provided by Theranos didn’t match to the degree that Celgene would have preferred and were “out of range,” The Verge reports. Sung told assistant U.S. attorney Robert Leach that she did not validate the Theranos technology.
Filed Under: Drug Discovery and Development